At the American Diabetes Association’s 76th Scientific Sessions this week, data is being presented from three studies that evaluated the accuracy and usability of blood glucose monitoring systems from Ascensia Diabetes Care
This is the first presentation of data for the Contour Next One blood glucose monitoring system evaluating ease-of-use in the hands of subjects with diabetes.
The Contour Next One system, which recently received CE Mark approval, features a wireless-enabled smart blood glucose meter that connects to the Contour Diabetes App on a smart phone. The app collects, stores and analyses patient blood glucose measurements received from the meter.
The study by Timothy Bailey, AMCR Institute, San Diego, assessed the usability of the Contour Next One blood glucose meter with the Contour Diabetes App in 43 individuals with type 1 and type 2 diabetes.
The study showed that 95.4% of subjects were able to sync their meter with the app and 95.4% were able to access and interpret the blood glucose displays. In addition, 98% of participants found that the blood glucose displays were understandable and 89.7% of subjects were able to initiate and use the bolus calculator feature.
Bailey, explained: “The Contour Diabetes App is designed to collect and display detailed information that may help people with diabetes with their management decisions.
“This study is the first to assess the system’s ease of use. Tools, such as the Contour Diabetes App, may help more people with diabetes and those who care for them to spot important patterns and trends, with the potential to lead to better health outcomes.”
An investigator-initiated study, presented by Guido Freckmann, evaluated the accuracy of the Contour Next Link 2.4 meter. This linking meter is wirelessly compatible and able to communicate with certain Medtronic insulin pump systems. The study also included five other meters that do not link to Medtronic insulin pumps, but are commonly used with them in various countries worldwide.
Capillary blood samples from 100 different subjects with diabetes were measured using each meter and compared to two different comparison methods (glucose oxidase and hexokinase). The Contour Next Link 2.4 was shown to meet these accuracy criteria for both comparison methods, according to Ascensia.
Lead investigator for the study, Freckmann, said: “Meter accuracy is particularly important for insulin pump users, as the blood glucose values are directly used to calculate the required insulin dose from the pump and to calibrate the continuous glucose monitoring sensor.
“High levels of accuracy are important to ensure pump users have safe and appropriate therapy.”
The outcomes of a study of the Contour Plus blood glucose monitoring system were also presented.
Michael Kloss, CEO of Ascensia Diabetes Care, added: “We are excited to share these new data from several important studies that are being presented at the American Diabetes Association’s 76th Scientific Sessions.
“The data from these studies shows our ongoing commitment at Ascensia Diabetes Care to scientific research and bold innovations that are aimed at offering new solutions to the diabetes community.”
The American Diabetes Association’s 76th Scientific Sessions are taking place in New Orleans from June 10-14, 2016.